Atazanavir (sulfate)

Atazanavir (BMS-232632) sulfate is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp) . Atazanavir sulfate is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM. Atazanavir sulfate inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death[1][2][3][4][5][6][7][8].

Product Specifications

CAS Number

[229975-97-7]

Product Name Alternative

BMS-232632 sulfate

UNSPSC

12352005

Hazard Statement

H318, H372

Target

Cytochrome P450; Endogenous Metabolite; HIV; HIV Protease; P-glycoprotein; SARS-CoV; Toll-like Receptor (TLR)

Type

Reference compound

Related Pathways

Anti-infection; Immunology/Inflammation; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Atazanavir-sulfate.html

Purity

99.68

Solubility

DMSO : 166 mg/mL (ultrasonic; warming) |H2O : < 0.1 mg/mL

Smiles

O=C(OC)N[C@@H](C(C)(C)C)C(NN(CC1=CC=C(C2=NC=CC=C2)C=C1)C[C@H](O)[C@H](CC3=CC=CC=C3)NC([C@H](C(C)(C)C)NC(OC)=O)=O)=O.O=S(O)(O)=O

Molecular Formula

C38H54N6O11S

Molecular Weight

802.93

Precautions

H318, H372

References & Citations

[4]Zhang G, et al. Long-term oral atazanavir attenuates myocardial infarction-induced cardiac fibrosis. Eur J Pharmacol. 2018 Jun 5;828:97-102.|[5]Fukushima K, et al. Effect of serum lipids on the pharmacokinetics of atazanavir in hyperlipidemic rats. Biomed Pharmacother. 2009 Nov;63 (9) :635-42. |[6]Pyrko P, et al. HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res. 2007 Nov 15;67 (22) :10920-8. |[7]Alomar FA, et al. Efavirenz, atazanavir, and ritonavir disrupt sarcoplasmic reticulum Ca2+ homeostasis in skeletal muscles. Antiviral Res. 2021 Mar;187:104975. |[8]Robillard KR, et al. Role of P-glycoprotein in the distribution of the HIV protease inhibitor atazanavir in the brain and male genital tract. Antimicrob Agents Chemother. 2014;58 (3) :1713-22.|[1]Havlir DV, et al. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis. 2004 Jun 1;38 (11) :1599-604.|[2]Wood R. Atazanavir: its role in HIV treatment. Expert Rev Anti Infect Ther. 2008 Dec;6 (6) :785-96.|[3]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

CYP3; HIV-1

Citation 01

BioRxiv. 2020 Apr.|Curr Protoc. 2021 Feb;1 (2) :e32.|Nat Commun. 2020 Apr 14;11 (1) :1792.|Nat Commun. 2020 Sep 4;11 (1) :4417.|Signal Transduct Target Ther. 2021 May 29;6 (1) :212.|Aging Cell. 2023 Jan;22 (1) :e13750.|Antimicrob Agents Chemother. 2020 Aug 20;64 (9) :e00872-20.|Faculty of Pharmacy in Hradec Králové Department of Pharmacological and Toxicology. University of Oxford. 2019 Jul.|Int J Antimicrob Agents. 2019 Dec;54 (6) :814-819.|J Photochem Photobiol A Chem. 2025 Nov 15;473:116930.|PLoS Biol. 2020 Jan 16;18 (1) :e3000599.|Research Square Print. 2022 May.